Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Corona Virus Disease 19 (Covid19)
  • Corona Virus Infection
  • Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)
Type
Interventional
Phase
Phase 3
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants are assigned to one of two groups in parallel for the duration of the study. One arm is the intervention arm: those receiving N-acetylcysteine (NAC). One arm is the control group : those not receiving N-acetylcysteine (NAC).Masking: Double (Participant, Care Provider)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligibility criteria will be randomized either to receive oral N-acetylcysteine or not along with the ins...

This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligibility criteria will be randomized either to receive oral N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy will be assessed using certain endpoints as follows: Markers of inflammation and oxidative stress Length of hospital stay Need for ventilation Mortality rate

Tracking Information

NCT #
NCT04792021
Collaborators
Misr International University
Investigators
Principal Investigator: Sara M. Sherkawy, B.S.P Misr International University Study Chair: Lamia El Wakeel, Professor Ain Shams University Study Director: Mona Schaalan, Professor Misr International University Study Director: Ayman Moharram, Professor El Kasr El Einy Hospital
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024